Daniel Drucker
Daniel Drucker is a Canadian scientist credited with identifying GLP-1, the peptide that underlies the mechanism of Ozempic, and he predicts that future developments will make these weight loss medications more accessible.
Not in the pool (under ¢1).
Recent news mentions
Dr. Daniel Drucker is best known for helping to discover the class of drugs that includes Ozempic.
Study to examine whether Ozempic can reduce the risk of blood cancer
Canada· 2026-02-26
Dr. Daniel Drucker’s research helped pave the way for Ozempic, the blockbuster GLP-1 class drug.
Skinny, Inc. Part 1: The Canadian connection to OzempicCanada· 2026-02-23
Dr. Daniel Drucker is a senior investigator at the Lunenfeld-Tanenbaum Research Institute and a pioneer of GLP-1 science.
The Canadian researcher whose discovery led to Ozempic is still making breakthroughsCanada· 2026-02-02
Canadian scientist Daniel Drucker played a key role in the discovery of GLP-1 drugs.
Canadians can benefit from tumbling prices on weight-loss drugsCanada· 2025-09-10
Daniel Drucker is a Canadian endocrinologist known for his contributions to the development of the weight loss drug Ozempic.
»Navdušenje nad zdravili za hujšanje je pretirano«
Slovenia· 2025-07-21Daniel Drucker was awarded for fundamental biological discoveries that led to new effective drugs for diabetes and obesity.
Un barómetro de la ciencia, el arte, la investigación y el pensamiento contemporáneos | Economía
Spain· 2025-06-21
Daniel Drucker is a Canadian endocrinologist who has significantly contributed to the understanding of GLP-1 and its implications for obesity treatment.
Daniel Drucker, padre de Ozempic: “Si se financiara para todo el mundo que quiere perder peso, no quedaría dinero para nada más” | Salud y bienestarSpain· 2025-06-18Dr. Daniel Drucker was among five researchers jointly awarded a US$3-million Breakthrough Prize in Life Sciences for discoveries leading to the development of a class of drugs that are now widely used in the treatment of Type 2 diabetes and obesity.
Daniel Drucker, Canadian co-discoverer of anti-obesity drugs, among 2025 Breakthrough Prize winnersCanada· 2025-04-06
Daniel Drucker was the first to identify GLP-1 and discusses future accessibility of weight loss medications.
Bajar de peso con Ozempic, una cuestión de clase y estatus | Bienestar | S ModaSpain· 2025-02-22
